Navigation Links
Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
Date:9/22/2008

s," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC's web site at http://www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
7. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Two ... increasing in applications as their effectiveness is ... Kalorama Information.  Kalorama Information says that while ... the most powerful tool in proteomic biomarker ... MS) through its traditional techniques has struggled ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... of 5,250,000 shares of its common stock at a ... net proceeds to Tandem from this offering are expected ... commissions and other estimated offering expenses payable by Tandem. ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  IRIDEX Corporation ... release its fourth quarter and full year 2014 financial results ...   In conjunction with the release, the Company will host ... p.m. Eastern Time on Thursday, March 5, 2015 ... business developments. Interested parties may access the live ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... URBANA, Ill., Dec. 6, 2011  Bayer HealthCare and ... outcomes-based contract for people with relapsing-remitting multiple sclerosis ... reduce the frequency of clinical exacerbations.  The agreement ... HealthCare in the U.S. and is defined by ...
... 2011 Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in ... cancer, announced today that a cancer research study to ... Aethlon Hemopurifier® to capture tumor-secreted exosomes from the blood ... approval to begin studies at the Sarcoma Oncology Center, ...
Cached Medicine Technology:Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 2Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 3Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 4Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes 2Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes 3
(Date:2/27/2015)... Those who self-injure, commonly ... misdiagnosed and therefore aren’t receiving effective treatment ... Jacksonville-based addiction treatment center Lakeview Health has ... Lakeview Professional Lecture Series to counselors, physicians, ... complicated condition. , “Self-injurious behaviors ...
(Date:2/27/2015)... 27, 2015 Clinovo, a leading provider ... Electronic Data Capture (EDC) at the CALBIO2015 ... 2nd and March 3rd at Booth # 141. ... DIY CRF and edit-check builder allowing Clinical Trials Managers ... of days, without any programming experience. Clinovo’s new pricing ...
(Date:2/27/2015)... February 27, 2015 Pipette.com announces their ... , price is only valid until the end of ... looking for a vortex mixer that allows for absolute ... founded in 1954 and is headquartered in Bohemia, New ... shakers, as well as other rockers, incubators, and hybridization ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Undocumented ... are documented to use Medicaid, the federal health ... according to a new study from UC Davis ... greatest predictor of farmworker use of Medicaid, which ... regardless of documentation status, was having children. ...
(Date:2/27/2015)... Royal River Natural Foods, a locally-owned independent natural health ... adults who got the most magnesium were less than half ... who got the least magnesium, with the largest benefit in ... part of the March 2015 issue of “ Natural Insights ... free each month for the Freeport community to learn more ...
Breaking Medicine News(10 mins):Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2
... , , NEW YORK, Sept. 16 ... Trustees, today announced the appointment of Alan Kadish, M.D., as senior ... , PHOTO: http://www.flickr.com/photos/tourocollege/3923514965/ ... institution in the United States. The college was founded by ...
... , SEBASTOPOL, Calif., Sept. 16 As ... yerba mate is quickly catching on as the newest organic ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090916/NE76510 ) , , ... the yerba mate beverage category, is driving yerba mate into the mainstream ...
... YONKERS, N.Y., Sept. 16 Welcome to ... Consumer Reports and ConsumerReportsHealth.org cover issues pertaining ... (including natural medicines), mental health, diet and nutrition, food safety, ... products, rates the effectiveness and affordability of prescription drugs, and ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- ... on September 10, reporters were informed that the,First World ... Endoscopy Physicians) and the First World Endoscopy Technology Expo,will ... , Professor Zhang Yangde, the ...
... used to alleviate the shortage of available liver donors. Accurate ... donor and recipient is crucial. Scholars of different countries established ... the most accurate for Chinese adults has remained unclear. ... published on August 28, 2009 in the World Journal ...
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
Cached Medicine News:Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 3Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 4Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 2Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 3Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Consumer Reports Health News 5Health News:Consumer Reports Health News 6Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3
Ideal for abdominal and back procedures....
Female High Waist Briefs...
Provides upper and lower arm support. Extends to the lower arm and across the shoulders. Has two columns of hook & eye closure for added adjustability....
Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Medicine Products: